Precision medicine in patients with solid cancer: - Molecular diagnostics for precision medicine in patients with solid cancer

Research Research programs Precision medicine in patients with solid cancer:

Our mission

We aim to enhance outcomes for patients with solid cancer, particularly those treated with targeted and immuno-therapies, by advancing innovative technologies such as molecular diagnostics, AI and integrative data analysis.

Goals

See some of the most important goals for this research program.

Listen

Goals

To foster multidisciplinary collaboration to develop and validate tumor-agnostic precision biomarkers and translate patient-focused research into clinical practice
To promote tumor-agnostic biomarker implementation through cross-departmental collaboration, enabling clinical translation across cancer types via shared expertise and infrastructure
To improve survival and quality of life for patients with solid cancers by enhancing personalized treatment allocation and ensuring timely access to the most effective therapies
To ensure the sustainability and affordability of precision medicine by integrating health-economic evaluations into the program

Research groups contributing to this research program

Cancer genomics

Richarda de Voer's research group focuses on the genetic predispositions and mutational processes that underly cancer development, especially in the context of development at an early age in Iife and concerning the development of multiple primary tumors throughout the life of a single individual.

Cancer pharmacology

Nielka van Erp's research group focuses on describing, explaining, understanding and modifying the pharmacokinetics of oral anticancer drugs.

Early health technology assessment

Janneke Grutters's research group develops and applies methodology to evaluate the (potential) value of innovations in healthcare, as of an early stage of development.

Spokesperson(s) for this research program

Spokesperson

dr. Niven Mehra

contact form